CN116942742B - Uric acid reducing traditional Chinese medicine composition and preparation method thereof - Google Patents
Uric acid reducing traditional Chinese medicine composition and preparation method thereof Download PDFInfo
- Publication number
- CN116942742B CN116942742B CN202311211158.9A CN202311211158A CN116942742B CN 116942742 B CN116942742 B CN 116942742B CN 202311211158 A CN202311211158 A CN 202311211158A CN 116942742 B CN116942742 B CN 116942742B
- Authority
- CN
- China
- Prior art keywords
- tea
- parts
- mixing
- pile fermentation
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 49
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 229940116269 uric acid Drugs 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 230000001603 reducing effect Effects 0.000 title claims abstract description 17
- 244000269722 Thea sinensis Species 0.000 claims abstract description 91
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 34
- 235000020279 black tea Nutrition 0.000 claims abstract description 34
- 240000008672 Gynura procumbens Species 0.000 claims abstract description 30
- 235000018457 Gynura procumbens Nutrition 0.000 claims abstract description 30
- 241000233779 Cyclocarya paliurus Species 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 235000013616 tea Nutrition 0.000 claims description 57
- 238000000855 fermentation Methods 0.000 claims description 42
- 230000004151 fermentation Effects 0.000 claims description 41
- 239000000463 material Substances 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 23
- 238000005303 weighing Methods 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 14
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 238000002386 leaching Methods 0.000 claims description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- 239000001116 FEMA 4028 Substances 0.000 claims description 6
- 241000288049 Perdix perdix Species 0.000 claims description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 6
- 229960004853 betadex Drugs 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 3
- 238000010025 steaming Methods 0.000 claims description 3
- 238000009461 vacuum packaging Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000011362 coarse particle Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 42
- 239000008280 blood Substances 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 28
- 241000700159 Rattus Species 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000002023 wood Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 201000001431 Hyperuricemia Diseases 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 6
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 150000002212 flavone derivatives Chemical class 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241001425752 Parthenos Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- -1 flavone glycoside Chemical class 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 2
- 235000007625 naringenin Nutrition 0.000 description 2
- 229940117954 naringenin Drugs 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- SBMBZNDXQINZKP-UHFFFAOYSA-N 2-ethoxy-5-hydroxynaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(OCC)=CC(=O)C2=C1O SBMBZNDXQINZKP-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000061121 Rauvolfia serpentina Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010054979 Secondary immunodeficiency Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XCGZWJIXHMSSQC-UHFFFAOYSA-N dihydroquercetin Natural products OC1=CC2OC(=C(O)C(=O)C2C(O)=C1)c1ccc(O)c(O)c1 XCGZWJIXHMSSQC-UHFFFAOYSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a uric acid reducing traditional Chinese medicine composition and a preparation method thereof, wherein the traditional Chinese medicine composition is prepared from the following raw materials: 5-10 parts of Anhua black tea bud tip, 3-5 parts of gynura procumbens, 3-5 parts of cyclocarya paliurus, 4-5 parts of parthenon tree and 2-3 parts of orange peel. The invention provides a traditional Chinese medicine composition which can reduce uric acid in a body, has better tolerance and safety for a user and has less side effect. The traditional Chinese medicine composition provided by the invention has good uric acid and blood sugar reducing effects.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine health care and preservation, in particular to a uric acid-reducing traditional Chinese medicine composition and a preparation method thereof.
Background
Hyperuricemia and hyperglycemia are common metabolic disorders. Uric acid is the final metabolite of purine compounds in humans, and hyperuricemia is caused by excessive uric acid in humans and by insufficient body excretion. Because the human body lacks enzymes capable of decomposing purine compounds, excessive uric acid can only be discharged out of the body by kidney metabolism, and once kidney metabolism dysfunction or food containing a large amount of purine is ingested, the uric acid concentration in the human body is overhigh, and the hyperuricemia can be diagnosed when the blood uric acid concentration of two non-same days is more than 420 umol/L. Uric acid concentration is too high, which can crystallize into the urinary acid salt, deposit in joint synovium, bursa, cartilage and other tissues, and cause gout. Modern medicine divides hyperuricemia into a formation increase type and a excretion decrease type according to causes, and selects uric acid generation inhibiting drugs such as allopurinol or uric acid excretion promoting drugs such as tribromouron, probenecid, benzenesulfonazone and the like according to renal function conditions. Although these drugs have remarkable uric acid lowering effect, side effects such as rash, fever, liver and kidney dysfunction, hematopoietic dysfunction, gout attack and the like are also large.
Therefore, it is expected by those skilled in the art to provide a Chinese medicinal composition which has good safety, less side effects, is suitable for long-term administration, and can effectively reduce uric acid in vivo, and a preparation method thereof.
Disclosure of Invention
First, the technical problem to be solved
In view of the above-mentioned shortcomings and drawbacks of the prior art, the present invention provides a Chinese medicinal composition which can effectively reduce uric acid in vivo, and has the advantages of good tolerance and safety for users and less side effects, and a preparation method thereof.
The traditional Chinese medicine composition provided by the invention has good uric acid and blood sugar reducing effects, is convenient to take, good in taste and low in side effect.
(II) technical scheme
In a first aspect, the invention relates to a uric acid reducing traditional Chinese medicine composition, which is prepared from the following raw materials: 5-10 parts of Anhua black tea bud tip, 3-5 parts of gynura procumbens, 3-5 parts of cyclocarya paliurus, 4-5 parts of parthenon tree and 2-3 parts of orange peel.
Preferably, the raw materials comprise the following components: 7 parts of Anhua black tea bud tip, 4.5 parts of gynura procumbens, 4.5 parts of cyclocarya paliurus, 4 parts of parthenon tree and 2.5 parts of orange peel. Wherein the bud tip of the Anhua black tea is the bud tip of the Anhua black tea which is stored for more than 15 years.
Preferably, the traditional Chinese medicine composition is decoction pieces, instant medicinal powder or oral liquid.
In a second aspect, the invention relates to a preparation method of a uric acid reducing traditional Chinese medicine composition, which is prepared from the following raw materials: 5-10 parts of Anhua black tea bud tip, 3-5 parts of gynura procumbens, 3-5 parts of cyclocarya paliurus, 4-5 parts of parthenon tree and 2-3 parts of orange peel; the preparation method comprises the following steps:
s1, stir-frying and pile fermentation of Anhua black tea:
s2, performing pile fermentation on gynura procumbens, green Qian Liusha green:
s3, weighing the cleaned partridge and orange peel, adding the cleaned partridge and orange peel, and preparing decoction pieces, instant medicinal powder or oral liquid by using the tea processed by the S1 and the medicinal materials processed by the S2.
According to a preferred embodiment of the present invention, S1 comprises the steps of:
(1) Weighing the bud tips of the Anhui black tea, adding 10-40g of water into each 100g of the bud tips of the Anhui black tea, uniformly mixing, putting into a tea frying machine for softening, frying for 10-30min at the temperature of 190-210 ℃ when the tea frying machine is put into a pot, and controlling the temperature of the leaves out of the pot to 55-65 ℃;
(2) Placing the tea leaves after softening in the step (1) into a pile fermentation chamber, wherein the temperature in the pile fermentation chamber is 20-35 ℃, the humidity is 80-90%, the pile fermentation height is 75-85cm, turning the pile when the temperature in the pile is raised to 75 ℃, and the pile fermentation time is 600-650h;
(3) And (3) drying the tea leaves subjected to pile fermentation in the step (2) in a dryer, and evaporating water at a high temperature of 70-75 ℃ for 35-40min, wherein the water content is kept at 8-12%.
According to a preferred embodiment of the present invention, S2 comprises the steps of:
(1) Respectively taking fresh gynura procumbens and cyclocarya paliurus, cleaning, sun-drying and sterilizing;
(2) Taking raw materials in the step (1), coarsely crushing, uniformly mixing, putting the coarse raw material particles into a de-enzyming machine, steaming at a high temperature of 250-300 ℃ for softening for 10min, and keeping the water content at 30-35%;
(3) Putting the medicinal materials in the step (2) into a rolling machine to roll the tea leaves into strips for 10min;
(4) Drying the medicinal materials in the step (3) in a tea frying machine, wherein the temperature of the tea frying machine in a pot is 250-300 ℃, frying for 20-30min, the temperature of the leaves in the pot is controlled to be 60-70 ℃, and the moisture is kept at 15-20%;
(5) Placing the medicinal materials in the step (4) into a pile fermentation chamber, keeping the temperature in the pile fermentation chamber at 25-28 ℃ and the humidity at 85-90%, turning the pile fermentation height at 65-75cm, and carrying out pile fermentation for 900-950h when the temperature in the pile is increased to 75 ℃;
(6) And (3) drying the medicinal materials subjected to pile fermentation in the step (5) in a dryer, and evaporating water at a high temperature of 70-75 ℃ for 40-45min.
According to a preferred embodiment of the present invention, S3 comprises the steps of: taking the tea leaves treated by the step S1 and the medicinal materials treated by the step S2, weighing the cleaned parthenon tree and orange peel, and mixing the tea leaves, the gynura procumbens, the cyclocarya paliurus, the parthenon tree and the orange peel according to the proportion of 5-10:3-5:3-5:4-5:2-3, mixing, quantitatively bagging in sterile environment, and sealing to obtain decoction pieces.
According to a preferred embodiment of the present invention, S3 comprises the steps of: taking the tea leaves treated by the step S1 and the medicinal materials treated by the step S2, weighing the cleaned parthenon tree and orange peel, and mixing the tea leaves, the gynura procumbens, the cyclocarya paliurus, the parthenon tree and the orange peel according to the proportion of 5-10:3-5:3-5:4-5: mixing 2-3 weight ratio, adding purified water 10-20 times of weight, decocting to 80-100deg.C for 30-40min, leaching for three times, mixing leaching solutions, filtering with 80-100 mesh sieve, concentrating the filtrate in rotary evaporator, and concentrating to obtain concentrated juice with volume of 1/3-1/4 of the filtrate before concentration; collecting concentrated juice, adding CaCl 2 Solution and beta-cyclodextrin, caCl 2 The addition amount is 2-2.5wt.% of the concentrated juice, the addition amount of the beta-cyclodextrin is 0.3-0.6wt.% of the concentrated juice, and the mixed solution is obtained after uniform mixing; spray drying the mixed solution under 1.0-3.5MPa, pulverizing to obtain 200-500 μm powder, quantitatively bagging under aseptic condition, and sealing to obtain instant powder.
According to a preferred embodiment of the present invention, S3 comprises the steps of: taking the tea leaves treated by the step S1 and the medicinal materials treated by the step S2, weighing the cleaned parthenon tree and orange peel, and mixing the tea leaves, the gynura procumbens, the cyclocarya paliurus, the parthenon tree and the orange peel according to the proportion of 5-10:3-5:3-5:4-5: mixing 2-3 weight parts, adding 3-5 times of purified water, and decocting to 80-100deg.C for 20-30min to obtain decoction; filtering with 100 mesh sieve, adding 1 times of brown sugar and 0.002 times of herba Menthae powder, and mixing; cooling to 30+ -5deg.C after sterilization, and low-temperature packaging by aseptic vacuum packaging method to obtain oral liquid.
(III) beneficial effects
The traditional Chinese medicine composition is prepared from raw materials of Anhua black tea bud tip, gynura procumbens, cyclocarya paliurus, parthenos and orange peel which are stored for more than 15 years. The black tea bud tip is a special microbial fermentation tea in China, has the effects of bitter taste, sweet taste, cool nature, heart, lung and stomach channel returning, and has the effects of clearing greasy, clearing head and eyes, promoting fluid production, relieving polydipsia, detoxifying and promoting urination, and a large number of researches prove that the black tea bud tip has the effects of reducing blood fat, reducing uric acid, reducing blood sugar, resisting oxidation and the like.
Compared with the traditional black tea, the black tea has longer fragrance, rich taste layering, reduced bitter and astringent taste and irritation, mellow taste and sweet taste, and increased medicine soup brightness by adopting the re-fermentation process of the Anhua black tea which is stored for more than 15 years. In addition, the black tea is aged for more than 15 years and contains rich tea polyphenol, soluble sugar, tea pigment, amino acid, caffeine, polyphenol substances and the like, so that mRNA expression levels of kidney uric acid reabsorption protein mGLT 9 and protein mURAT can be reduced by inhibiting liver XOD and ADA activities, on one hand, uric acid generation is inhibited, on the other hand, uric acid excretion in the kidney is promoted, and in-vivo uric acid level is reduced; the activity of enzyme related to sugar metabolism is influenced, the activity of islet cells is protected, the activity of transport carriers related to sugar metabolism is inhibited, the free radicals in the body are eliminated, the beta islet cells are protected, the intestinal flora is regulated, and the blood sugar level in the body is regulated. The black tea is stored for a long time, has the oxidation effect after a long time, is milder and has no stimulation, can promote the metabolism of blood, promote digestion, nourish intestines and stomach, reduce three highs, reduce blood sugar and have medicinal effects, and the longer the black tea is stored, the higher the oxidation degree, and the more mellow the taste of tea soup.
The gynura procumbens has the advantages that the gynura procumbens is spicy and slightly bitter in taste and cool in nature, has the effects of diminishing inflammation and dissipating heat, promoting blood circulation and removing blood stasis, relieving swelling and pain, protecting liver and detoxifying and the like, contains chemical active ingredients such as flavonoid, tea polysaccharide, phenols, nitrogen-containing compounds, terpenes, fatty acids, steroids and the like, and the content of the active ingredients such as flavone, tea polyphenol, tea polysaccharide and the like in the gynura procumbens fermented tea subjected to fermentation treatment is changed in a series of biochemical reactions, so that the quality of the gynura procumbens tea is greatly improved, the contents of the active ingredients such as flavone, tea polyphenol, tea polysaccharide and the like are increased, lipid synthesis and absorption are inhibited, the concentration of nerve transmission substances in the brain is regulated, the effects of uric acid reduction, blood sugar reduction and blood pressure reduction are achieved, and sub-health states are relieved.
Cyclocarya paliurus is a special single plant of China, and the cyclocarya paliurus Liu Na obtained by fermentation contains rich organic influence substances such as tea polysaccharide, amino acid, flavone and the like, is also rich in microelements such as zinc, selenium, germanium and the like which are necessary for a human body, and improves the sensitivity and the function of insulin receptors on cell membranes of peripheral tissues by targeting and selecting pancreas parts, so that blood sugar and blood uric acid are stably reduced, and a certain kidney protection effect is generated. In particular, the cyclocarya paliurus tea obtained by the fermentation process has higher selenium content, can effectively remove free radicals in the body, and has a greater health care effect on the human body.
The parthenocarpic wood refers to a woody septum in walnut fruits, the surface of the parthenocarpic wood is light brown, tan or brownish black, the surface of the parthenocarpic wood is slightly glossy, and the parthenocarpic wood has bitter taste, and is written in "herbal renewing": the heart wood is divided into spleen and kidney meridians, and has the effects of strengthening spleen and tonifying kidney. Modern medical research shows that the core wood is rich in catechin and flavone glycoside, especially for visceral fat, has the functions of increasing the elasticity of micro blood vessels, reducing blood fat and dissolving fat, can effectively control obesity, can remove free radicals, delay aging, inhibit blood pressure and blood sugar, reduce cholesterol, and has the special effects of resisting radiation and ultraviolet. The dihydroquercetin and 2-ethoxyjuglone can inhibit tumor by inhibiting DNA synthesis of tumor cells, damaging mitochondria of tumor cells, and destroying mitochondrial inclusion; the naringenin is a natural compound which can regulate the level of T lymphocytes in the organism, improve the immune function of the organism and inhibit the growth of tumors, and has good effects on repairing secondary immunodeficiency caused by tumors or radiotherapy and chemotherapy and killing cancer cells; the beta-sitosterol and naringenin have obvious effects of enhancing the activity of superoxide dismutase (SOD), scavenging free radicals, resisting oxidation and reducing serum cholesterol; the parthenocarpic wood also contains vomit-promoting devilpepper, which is a compound with obvious blood pressure reducing effect, and can improve blood supply of organs such as cardiac muscle, kidney, liver and the like by dilating blood vessels so as to achieve the effect of regulating blood pressure.
Orange peel is a common traditional Chinese medicine in China, and various researches prove that the orange peel has various pharmacological activities and has been used as an auxiliary therapeutic drug for improving obesity, hyperlipidemia and hyperglycemia. Pharmacological analysis shows that the compound contains rich flavonoid compounds including nobiletin, hesperetin, sweet orange flavone and the like, has the characteristics of anti-inflammatory, antioxidant, antiallergic, anti-obesity, anti-sugar, cardiovascular protection, anticancer and the like, has obvious effects on inhibiting the activities of xanthine oxidase and xanthine dehydrogenase, and can achieve the therapeutic purpose of reducing uric acid.
Detailed Description
The present invention will be described more fully hereinafter with reference to the preferred embodiments for the purpose of facilitating understanding of the present invention, but the scope of protection of the present invention is not limited to the specific embodiments described below. Unless defined otherwise, all technical and scientific terms used hereinafter have the same meaning as commonly understood by one of ordinary skill in the art. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the scope of the present invention.
The various reagents and materials used in the present invention are commercially available or may be prepared by known methods unless otherwise specified.
Example 1
The present example prepares uric acid lowering decoction pieces of a traditional Chinese medicine composition, which require preparation of the tips of Anhua black tea buds for more than 15 years, and weighing gynura procumbens, cyclocarya paliurus, parthenon and orange peel. The preparation method of the traditional Chinese medicine composition decoction pieces comprises the following steps:
the first step: parching and re-piling to ferment and security black tea:
(1) Weighing Anhua black tea tooth tips, adding 30g of water into every 100g of Anhua black tea tooth tips, uniformly mixing, putting into a tea frying machine for softening, wherein the temperature of the tea frying machine is 200 ℃, frying for 20min, and the temperature of the tea leaves discharged from the pot is controlled to be 60 ℃.
(2) And (3) putting the tea leaves which are softened in the step (1) into a pile fermentation chamber, wherein the temperature in the pile fermentation chamber is 30 ℃, the humidity is 85%, the pile fermentation height is 80cm, and turning the pile when the temperature in the pile is increased to 75 ℃, and the pile fermentation time is 600 hours.
(3) And (3) drying the tea leaves subjected to pile fermentation in the step (2) in a dryer, evaporating water at a high temperature of 75 ℃ for 35min, and keeping the water at 10%.
And a second step of: fermenting fresh gynura procumbens, cyclocarya paliurus and pile fermentation:
(1) Weighing fresh gynura procumbens and cyclocarya paliurus, cleaning raw materials, sun-drying the cleaned raw materials, and sterilizing.
(2) And (3) coarse crushing the raw materials in the step (1), uniformly mixing, putting the coarse raw material particles into a de-enzyming machine, steaming at a high temperature of 300 ℃ for softening for 10min, and keeping the moisture at 30%.
(3) And (3) putting the medicinal materials in the step (2) into a rolling machine to roll the tea leaves into strips for 10min.
(4) And (3) drying the medicinal materials in the step (3) in a tea frying machine, wherein the temperature of the tea frying machine in a pot is 300 ℃, the tea frying is carried out for 25min, the temperature of the leaves in the pot is controlled to be 65 ℃, and the moisture is kept at 18%.
(5) And (3) placing the medicinal materials in the step (4) into a pile fermentation chamber, wherein the temperature in the pile fermentation chamber is kept at 25 ℃, the humidity is 90%, the pile fermentation height is 70cm, and turning the pile when the temperature in the pile is increased to 75 ℃, and the pile fermentation time is 900 hours.
(6) And (3) drying the medicinal materials subjected to pile fermentation in the step (5) in a dryer, and evaporating water at a high temperature of 75 ℃ for 40min.
And a third step of: the preparation method of the traditional Chinese medicine composition decoction pieces comprises the following steps:
taking the dry tea obtained in the first step and the medicinal materials obtained in the second step, weighing 7 parts by weight of the bud tip of the Anhua black tea, 4.5 parts by weight of the gynura procumbens, 4.5 parts by weight of cyclocarya paliurus, weighing 4 parts by weight of the cleaned partridge and 2.5 parts by weight of the orange peel, respectively coarsely crushing, uniformly mixing, quantitatively bagging in a sterile environment, and sealing to obtain the decoction pieces.
Example 2
The instant medicinal powder of the traditional Chinese medicine composition for reducing uric acid is prepared in the embodiment, wherein the instant medicinal powder is prepared by placing the black tea bud tips of the Anhua tea over 15 years, and weighing the gynura procumbens, the cyclocarya paliurus, the parthenos and the orange peel. The preparation of the instant powder is shown in example 1 in the first and second steps, with only the third step being different.
And a third step of: the preparation method of the instant medicinal powder comprises the following steps:
taking the dry tea obtained in the first step and the medicinal material obtained in the second step, weighing 7 parts by weight of Anhua black tea bud tip, 4.5 parts by weight of gynura procumbens and 4.5 parts by weight of cyclocarya paliurus, weighing 4 parts by weight of cleaned partridge and 2.5 parts by weight of orange peel, adding 12 times of purified water, boiling to 100 ℃, boiling for 40min, leaching for three times, and merging leaching solutions. Filtering the leaching solution by using a 100-mesh screen, and concentrating the filtrate in a rotary evaporator, wherein the volume of the concentrated juice is 1/3 of that of the filtrate before concentration; collecting concentrated juice, adding CaCl 2 Solution and beta-cyclodextrin, caCl 2 The addition amount is 2.5wt.% of the concentrated juice, and the addition amount of the beta-cyclodextrin is 0.5wt.% of the concentrated juice, and the mixed solution is obtained after uniform mixing. Drying in spray dryer under 2.5MPa, pulverizing, sieving to obtain 200-500 μm powder, quantitatively bagging under aseptic condition, and sealing to obtain instant powder.
Example 3
The preparation of uric acid-reducing oral liquid of the traditional Chinese medicine composition in this embodiment requires preparation of the black tea bud tip aged for more than 15 years, and weighing of gynura procumbens, cyclocarya paliurus, parthenon tree and orange peel. The preparation of the instant powder is shown in example 1 in the first and second steps, with only the third step being different.
And a third step of: the preparation method of the oral liquid comprises the following steps:
taking the dried tea leaves obtained in the first step and the medicinal materials obtained in the second step, weighing 7 parts by weight of Anhua black tea bud tip, 4.5 parts by weight of gynura procumbens and 4.5 parts by weight of cyclocarya paliurus, weighing 4 parts by weight of cleaned partridge and 2.5 parts by weight of orange peel, adding 50 parts by weight of purified water, and boiling to 100 ℃ for 30 minutes to obtain the medicinal soup. Filtering the decoction by a 100-mesh sieve, adding 1 part by weight of brown sugar and 0.002 part by weight of mint powder for seasoning, and uniformly mixing. Cooling to 30deg.C after sterilizing, and low-temperature packaging by aseptic vacuum packaging method to obtain oral liquid.
Comparative example 1
The comparative example differs from example 3 only in that the comparative example directly uses the tips of the Anhui black tea buds that were aged for more than 15 years, and only the tips were placed into a tea frying machine for softening and a dryer for drying so that the water content was kept at 8-12%, and no secondary pile fermentation was performed. The rest conditions and steps are as described in example 3, and oral liquid is prepared.
Comparative example 2
The comparative example differs from example 3 only in that the comparative example used Gynura procumbens and cyclocarya paliurus which were treated only with the enzyme deactivation and tea frying machine, but the pile fermentation was not performed on the Gynura procumbens and cyclocarya paliurus. The rest conditions and steps are as described in example 3, and oral liquid is prepared.
Comparative example 3
The difference between this comparative example and example 3 is that the oral liquid material of this comparative example does not contain divided wood and orange peel. The rest conditions and steps are as described in example 3, and oral liquid is prepared.
Efficacy verification of the traditional Chinese medicine composition:
in order to verify the efficacy of the traditional Chinese medicine composition in reducing uric acid and blood sugar, the prevention and alleviation effects of the oral liquid in the process of hyperuricemia of rats are researched by establishing a rat hyperuricemia model and taking a model rat as a research object. The test includes the following:
(1) Molding a hyperglycemic rat: 2.10g of citric acid was added with 100mL of double distilled water to prepare a 0.1mmol/L citric acid solution, 2.94g of sodium citrate was added with 100mL of double distilled water to prepare a 0.1mmol/L sodium citrate solution, the two solutions were mixed in a ratio of 1:1 to prepare a citric acid buffer (pH 4.5), and Streptozotocin (STZ) was dissolved therein to prepare a 1% STZ solution.
SD male rats with the weight of (200+/-20) g are purchased, 66 normal SD rats are adaptively fed for 1 week, 50 healthy rats are selected and randomly divided into a model group and a treatment group (an oral liquid in example 3), 25 rats in each group are randomly injected with a freshly prepared STZ solution in the abdominal cavity, the injection dose is 60mg/kg, the fasting blood glucose concentration is measured after 72 hours, and the fasting blood glucose concentration of the rats is more than or equal to 16.7mmol/L and is manifested as symptoms such as polydipsia, polyphagia, diuresis and the like, which indicates that the molding of the hyperglycemic rats is successful.
The fasting blood glucose concentration was measured before the start of the test, rats in the treatment group were each filled with 600mg/kg of oral liquid (recommended average daily dose for adults 6g, and according to average weight for men and women of adults 60kg, the daily dose was 100mg/kg., which is about 6 times the daily dose for rats calculated from unit volume, and 600 mg/kg), 9:00 am each day, and the model group was given an equal volume of distilled water for 30 days, and after 12 h days of fasting, the tail was cut, and blood was taken, respectively, to measure the fasting blood glucose concentration.
(2) Hyperuricemia model group: male SPF-grade SD rats were purchased for 84, 6-8 weeks old, and the body mass was 180-220 g/rat. Rats were fed adaptively for 1 week and then divided into a control group (control group was filled with distilled water daily), a model group, an allopurinol group, a control group 1 (comparative example 1 oral liquid), a control group 2 (comparative example 2 oral liquid), a control group 3 (comparative example 3 oral liquid), and a treatment group (example 3 oral liquid), each group being 12. The other groups except the control group were molded by administering 25mg/kg adenine and 300mg/kg potassium oxazinate, respectively, 1 time per day, and stomach was continuously irrigated for 3 weeks. Elevated blood uric acid suggests successful molding.
Starting administration treatment from the induction model, and pouring the allopurinol group into the stomach according to the dosage of 20mg/kg of allopurinol; the treatment group, the comparison group 1 and the comparison group 3 are subjected to gastric lavage according to the dosage of 600 mg/kg; the control group is given the same dose of distilled water for gastric lavage; 1 time per day for 3 consecutive weeks. And (3) observing the indexes: serum Uric Acid (UA) before and after administration, blood is collected from the retroorbital venous plexus of a rat by about 1.5 ml, naturally coagulated at 25 ℃ at room temperature for 1h, centrifuged at 2500r/min for 5min, and the serum is separated and assayed for UA.
(3) The experimental results are as follows:
TABLE 1 comparison of blood glucose concentrations in rats of each group)
。
Note that: * The representation is significantly different from the model set (P<0.05) ，。
As can be seen from Table 1, the blood glucose concentration of rats in the treatment group was reduced after 30 days of continuous gastric lavage with 600mg/kg oral liquid, and the blood glucose concentration was relatively stable after 10 days. The blood sugar concentration of the 10d, 20d and 30d treatment groups is obviously different from that of the model group (P is less than 0.05), which shows that the blood sugar concentration of the rats of the long-term gastric lavage oral liquid is lower than that of the model group.
TABLE 2 comparison of blood uric acid concentrations in rats of each group)
。
Note that: * The representation is significantly different from the model set (P<0.05)，。
As can be seen from Table 2, the differences were statistically significant (P > 0.05) in comparison with blood uric acid from the groups prior to administration. After administration, the blood uric acid level of the model group is increased compared with that of the control group, which indicates that the model is successfully manufactured. Compared with the model group, allopurinol group, comparison group 1 to comparison group 3 and treatment group showed significantly reduced blood uric acid, and the difference was statistically significant. Allopurinol group decreased blood uric acid concentration in rats compared to pre-dose, while treatment group could not decrease blood uric acid concentration compared to pre-dose, but increased blood uric acid concentration by about 10.6% before and after dose in treatment group compared to model group by nearly 56%; blood uric acid concentrations were increased by 22.7%, 25.4%, 22.2% before and after dosing of control 1 to control 3. This demonstrates that the oral liquid of the present invention can effectively suppress the rate of elevation of blood uric acid under the same feeding and disturbing conditions as compared with the comparative groups 1 to 3.
The above experiment is described by taking the oral liquid of example 3 as an example, but the decoction pieces of example 1 and the instant medicinal powder of example 2 have similar effects.
Clinical cases
Zhao Mou: men, 55 years old and 3 months in 2020, are treated in a traditional Chinese medicine university affiliated hospital in Jiangxi because of physical discomfort, and the examination shows that the fasting blood sugar, postprandial blood sugar and serum uric acid are higher, and the oral liquid is orally taken twice a day, 6g each time, and is taken twice a day and in the morning and evening respectively, and the fasting blood sugar, postprandial blood sugar and serum uric acid are reduced after continuous taking for 1 month, and the fasting blood sugar, postprandial blood sugar and serum uric acid are reduced to normal levels after continuous taking for 2 months.
Wu Mou: women, 50 years old, 6 months in 2020, find fasting blood sugar, postprandial blood sugar, serum uric acid are higher than normal level because of unit physical examination, give decoction pieces of the invention, 6g each time, warm boiled water take, take twice a day, take each morning and evening, recheck after 1 month continuously, find fasting blood sugar, postprandial blood sugar, serum uric acid reduce, continue taking after 2 months, fasting blood sugar, postprandial blood sugar, serum uric acid reduce to the normal level.
Liu Mou: the male is aged 53, 6 months of 2021, and the fasting blood sugar, postprandial blood sugar and serum uric acid are higher due to the physical examination of the unit, 6g of the instant medicinal powder is orally taken each time, twice a day, and once a day and a night, and the instant medicinal powder is continuously taken for 1 month and then is rechecked, and the fasting blood sugar, postprandial blood sugar and serum uric acid are reduced to normal levels after the administration is continued for 2 months.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and not for limiting the same; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the invention.
Claims (4)
1. The preparation method of the uric acid reducing traditional Chinese medicine composition is characterized by comprising the following raw materials: 5-10 parts of Anhua black tea bud tip, 3-5 parts of gynura procumbens, 3-5 parts of cyclocarya paliurus, 4-5 parts of parthenon tree and 2-3 parts of orange peel; the preparation method comprises the following steps:
s1, tea treatment: parching and pile fermentation of Anhua black tea;
s101, weighing the bud tips of the Anhua black tea, adding 10-40g of water into each 100g of the bud tips of the Anhua black tea, uniformly mixing, putting into a tea frying machine for softening, wherein the temperature of the tea frying machine is 190-210 ℃, frying for 10-30min, and the temperature of the tea leaves is controlled to be 55-65 ℃; the black tea bud tip is the black tea bud tip which is aged for more than 15 years;
s102, placing the tea leaves after softening in the step S101 into a pile fermentation chamber, wherein the temperature in the pile fermentation chamber is 20-35 ℃, the humidity is 80-90%, the pile fermentation height is 75-85cm, turning the pile when the temperature in the pile is increased to 75 ℃, and the pile fermentation time is 600-650h;
s103, placing the tea leaves subjected to pile fermentation in the step S102 into a dryer for drying, and evaporating water at a high temperature of 70-75 ℃ for 35-40min, wherein the water is kept at 8-12%;
s2, medicinal material treatment: performing pile fermentation on gynura procumbens, green Qian Liusha green and blue;
s201, respectively taking fresh gynura procumbens and cyclocarya paliurus, cleaning, sun-drying and sterilizing;
s202, coarse crushing and uniformly mixing raw materials in the step S201, putting the raw material coarse particles into a de-enzyming machine, steaming at a high temperature of 250-300 ℃ for softening for 10min, and keeping the water content at 30-35%;
s203, putting the medicinal materials in the step S202 into a rolling machine to roll the medicinal materials into strips for 10min;
s204, drying the medicinal materials in the step S203 in a tea frying machine, wherein the temperature of the tea frying machine is 250-300 ℃, frying for 20-30min, the temperature of the leaves of the tea frying machine is controlled to be 60-70 ℃, and the moisture is kept at 15-20%;
s205, placing the medicinal materials in the step S204 into a pile fermentation chamber, keeping the temperature in the pile fermentation chamber at 25-28 ℃ and the humidity at 85-90%, wherein the pile fermentation height is 65-75cm, turning the pile when the temperature in the pile rises to 75 ℃, and the pile fermentation time is 900-950h;
s206, taking the medicinal materials subjected to pile fermentation in the step S205, putting the medicinal materials into a dryer for drying, and evaporating water at a high temperature of 70-75 ℃ for 40-45min;
s3, weighing the cleaned partridge and orange peel by using the tea leaves processed in the step S1 and the medicinal materials processed in the step S2, and preparing decoction pieces, instant medicinal powder or oral liquid.
2. The method of claim 1, wherein step S3 comprises the steps of: taking the tea leaves processed in the step S1 and the medicinal materials processed in the step S2, weighing the cleaned parthenon tree and orange peel, and mixing the tea leaves, the gynura procumbens, the cyclocarya paliurus, the parthenon tree and the orange peel according to the proportion of 5-10:3-5:3-5:4-5:2-3, mixing, quantitatively bagging in sterile environment, and sealing to obtain decoction pieces.
3. The method of claim 1, wherein step S3 comprises the steps of: taking the tea leaves treated by the step S1 and the medicinal materials treated by the step S2, weighing the cleaned parthenon tree and orange peel, and mixing the tea leaves, the gynura procumbens, the cyclocarya paliurus, the parthenon tree and the orange peel according to the proportion of 5-10:3-5:3-5:4-5: mixing 2-3 weight ratio, adding purified water 10-20 times of weight, decocting to 80-100deg.C for 30-40min, leaching for three times, mixing leaching solutions, filtering with 80-100 mesh sieve, concentrating the filtrate in rotary evaporator, and concentrating to obtain concentrated juice with volume of 1/3-1/4 of the filtrate before concentration; collecting concentrated juice, adding CaCl 2 Solution and beta-cyclodextrin, caCl 2 The addition amount is 2-2.5wt.% of the concentrated juice, the addition amount of the beta-cyclodextrin is 0.3-0.6wt.% of the concentrated juice, and the mixed solution is obtained after uniform mixing; spray drying the mixed solution under 1.0-3.5MPa, pulverizing to obtain 200-500 μm powder, quantitatively bagging under aseptic condition, and sealing to obtain instant powder.
4. The method of claim 1, wherein step S3 comprises the steps of: taking the tea leaves treated by the step S1 and the medicinal materials treated by the step S2, weighing the cleaned parthenon tree and orange peel, and mixing the tea leaves, the gynura procumbens, the cyclocarya paliurus, the parthenon tree and the orange peel according to the proportion of 5-10:3-5:3-5:4-5: mixing 2-3 weight parts, adding 3-5 times of purified water, and decocting to 80-100deg.C for 20-30min to obtain decoction; filtering with 100 mesh sieve, adding 1 times of brown sugar and 0.002 times of herba Menthae powder, and mixing; cooling to 30+ -5deg.C after sterilization, and low-temperature packaging by aseptic vacuum packaging method to obtain oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311211158.9A CN116942742B (en) | 2023-09-20 | 2023-09-20 | Uric acid reducing traditional Chinese medicine composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311211158.9A CN116942742B (en) | 2023-09-20 | 2023-09-20 | Uric acid reducing traditional Chinese medicine composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116942742A CN116942742A (en) | 2023-10-27 |
| CN116942742B true CN116942742B (en) | 2023-12-19 |
Family
ID=88447722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311211158.9A Active CN116942742B (en) | 2023-09-20 | 2023-09-20 | Uric acid reducing traditional Chinese medicine composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116942742B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103262919A (en) * | 2013-06-17 | 2013-08-28 | 湖南省茶叶研究所 | Processing method for improving quality of Tianjian raw dark green tea |
| CN103493916A (en) * | 2013-09-26 | 2014-01-08 | 谢大高 | Secondary-fermentation black tea as well as production method and production device thereof |
| CN105379886A (en) * | 2015-11-11 | 2016-03-09 | 贺志弘 | Black tea composition capable of preventing and treating hyperuricemia and preparation method thereof |
| CN105832794A (en) * | 2016-06-06 | 2016-08-10 | 江西本草天工科技有限责任公司 | Application of Gynura procumbens to production of medicine, healthcare food or functional food for preventing and treating hyperuricemia |
| CN108402224A (en) * | 2018-05-15 | 2018-08-17 | 肖胜君 | A kind of blue or green money willow black tea and preparation method thereof |
| CN109480006A (en) * | 2018-12-07 | 2019-03-19 | 成都四海生物科技有限公司 | The ferment making technique of Gynura procumbens (Lour.) Merr fermented tea |
| CN110839730A (en) * | 2019-11-28 | 2020-02-28 | 江西轩豪中药饮片有限公司 | Stacked fermentation method of cyclocarya paliurus decoction pieces |
-
2023
- 2023-09-20 CN CN202311211158.9A patent/CN116942742B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103262919A (en) * | 2013-06-17 | 2013-08-28 | 湖南省茶叶研究所 | Processing method for improving quality of Tianjian raw dark green tea |
| CN103493916A (en) * | 2013-09-26 | 2014-01-08 | 谢大高 | Secondary-fermentation black tea as well as production method and production device thereof |
| CN105379886A (en) * | 2015-11-11 | 2016-03-09 | 贺志弘 | Black tea composition capable of preventing and treating hyperuricemia and preparation method thereof |
| CN105832794A (en) * | 2016-06-06 | 2016-08-10 | 江西本草天工科技有限责任公司 | Application of Gynura procumbens to production of medicine, healthcare food or functional food for preventing and treating hyperuricemia |
| CN108402224A (en) * | 2018-05-15 | 2018-08-17 | 肖胜君 | A kind of blue or green money willow black tea and preparation method thereof |
| CN109480006A (en) * | 2018-12-07 | 2019-03-19 | 成都四海生物科技有限公司 | The ferment making technique of Gynura procumbens (Lour.) Merr fermented tea |
| CN110839730A (en) * | 2019-11-28 | 2020-02-28 | 江西轩豪中药饮片有限公司 | Stacked fermentation method of cyclocarya paliurus decoction pieces |
Non-Patent Citations (6)
| Title |
|---|
| Tea and its components reduce the production of uric acid by inhibiting xanthine oxidase;Dan Wu et al.;《Food & Nutrition Research》;第66卷;第8239页 * |
| 二次渥堆对安化黑毛茶品质形成的影响研究;曾斌 等;《食品工业科技》;第36卷(第17期);第127-131页 * |
| 云南分心木提取物对小鼠高尿酸血症模型治疗作用研究;张伟 等;《天然产物研究与开发》;第33卷;摘要 * |
| 安化黑茶降尿酸作用及其机理;龚雨顺 等;《中国茶叶》;第45卷(第4期);摘要 * |
| 赵春杰.《告别痛风》.华龄出版社,2020,第124页. * |
| 青钱柳化学成分及抗代谢性疾病药理作用研究进展;徐若宸 等;《中草药》;第54卷(第9期);摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116942742A (en) | 2023-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101624570B (en) | Method for cultivating cultured ganoderma lucidum with Chinese medicaments and method for preparing cultured ganoderma lucidum health-care product | |
| KR100404979B1 (en) | Drink for getting rid of the aftereffects of the night's drink and manufacturing method thereby | |
| CN107648454A (en) | A kind of kidney tonifying cream taste and preparation method thereof | |
| CN107751993A (en) | A kind of antifatigue cream taste and preparation method thereof | |
| CN107136370A (en) | A kind of herb fermenting beverage with antitumor efficacy and preparation method thereof | |
| KR101830048B1 (en) | Food composition for improvement obesity or improvement hyperlipidemic with the extract of Terminalia chebula fruit and Phyllanthus emblica | |
| CN106617049A (en) | Propolis healthcare product with moringa oleifera leaf extract and method for preparing propolis healthcare product | |
| CN1403017A (en) | Selenium-rich konjaku-green tea health food | |
| CN116942742B (en) | Uric acid reducing traditional Chinese medicine composition and preparation method thereof | |
| CN101427833B (en) | Process for preparing low-alcohol beverage of rice | |
| CN110693029A (en) | Mulberry leaf and bitter gourd functional food capable of reducing blood sugar | |
| KR20040101598A (en) | Active fraction having weight loss effects on Leprdb/Leprdb mice isolated from medicinal plants | |
| CN104431163A (en) | Lucid ganoderma green tea and preparation method thereof | |
| CN108260682A (en) | A kind of hypoglycemic, reducing blood lipid and the health protection tea of blood pressure lowering | |
| CN107712890A (en) | A kind of antitoxic heart-soothing and sedative cream taste and preparation method thereof | |
| CN102308989B (en) | Health care composition of formica rufa, grape and propolis extracts | |
| KR101093006B1 (en) | Method for producing functional health food containing bezoar bovis used microbes and the functional health food produced by the same | |
| CN111729056A (en) | Anticancer medicine composition and its prepn | |
| CN111150065A (en) | Application of sea-buckthorn water-soluble extract in preparation for inhibiting Tau protein phosphorylation | |
| CN110679688A (en) | Honey oolong tea beverage | |
| CN109620858A (en) | The integration of drinking and medicinal herbs preparation for preventing and treating diabetes | |
| CN111773263A (en) | Pharmaceutical composition for treating kidney cancer and preparation method thereof | |
| CN108635560A (en) | A kind of Chinese medicine and preparation method thereof for treating lymthoma | |
| CN108720013A (en) | The formula and processing technology of the health food of one group of Soboring-up liver-protecting being made of fructose and tea extract | |
| CN107384688A (en) | The brewing method of shrub lespedeza red clover health preserving wine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |